Latest News of ZEV
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
By Yahoo! Finance |
3 weeks ago
Miplyffa, in combination with Johnson & Johnson's enzyme inhibitor Zavesca, is approved by the FDA to treat neurological symptoms in adults and children with NPC, a rare genetic disease. This marks a ...
US FDA approves Zevra's treatment for rare genetic disease
By Yahoo! Finance |
3 weeks ago
The U.S. FDA approved Zevra Therapeutics' drug for Neimann-Pick disease type C, a rare genetic disorder. The oral drug, Miplyffa, can now be used in combination with miglustat to treat neurological sy...
Ana Maria Knezevich missing: Federal authorities say no blood found at scene where Florida woman disappeared
By Fox News |
2 months ago
David Knezevich's attorney denies involvement in his wife's disappearance in Spain. Lack of forensic evidence and inconsistent findings raise doubts about the case against him. Ana and David ran a suc...
-
ZVRA Stock Price | Zevra Therapeutics Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
By MarketWatch | 2 months agoZevra Therapeutics, Inc. is a specialty pharmaceutical company focused on developing prodrugs for medical conditions like ADHD and pain. Founded in 2006, it utilizes Ligand Activated Therapy to target...
-
We're A Little Worried About Zevia PBC's (NYSE:ZVIA) Cash Burn Rate
By Yahoo! Finance | 2 months agoOwning shares of unprofitable businesses can be lucrative, as seen with Amazon. However, Zevia PBC's increasing cash burn rate and short cash runway are concerning. Shareholders should monitor the com...
-
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
By Yahoo! Finance | 3 months agoThe FDA will hold a meeting with the Genetic Metabolic Diseases Advisory Committee to review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C. Analysts are optimistic about approval des...
-
Breakeven On The Horizon For Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
By Yahoo! Finance | 3 months agoZevra Therapeutics, Inc. is nearing breakeven, with analysts predicting profitability by 2026. The company's growth rate is estimated at 65% annually, but its high debt level poses a risk....